Amarin

Amarin eyes blockbuster Vascepa sales as FDA grants heart-helping label expansion
Amarin eyes blockbuster Vascepa sales as FDA grants heart-helping label expansion
Fierce Pharma
Amarin
Vascepa
FDA
Cardiovascular
Flag link:
2 Top Biotech Buyout Candidates
2 Top Biotech Buyout Candidates
Motley Fool
M&A
Amarin
Vascepa
Aurinia Pharmaceuticals
voclosporin
Flag link:
4 FDA Dates Biotech Investors Should Circle in December
4 FDA Dates Biotech Investors Should Circle in December
Motley Fool
FDA
Amgen
anti-inflammatories
ABP710
Bausch Health Companies
acne
IDP-123
Intra-Cellular Therapies
lumateperone
schizophrenia
Vascepa
Amarin
Flag link:
Go or no go? Vascepa’s finale and Allergan's pain relief
Go or no go? Vascepa’s finale and Allergan's pain relief
EP Vantage
FDA
Amarin
Vascepa
Allergan
migraines
ubrogepant
Flag link:
Before 2019 closes, the FDA has 3 key approval decisions to make
Before 2019 closes, the FDA has 3 key approval decisions to make
Biopharma Dive
Allergan
ubrogepant
migraines
Amarin
Vascepa
Intra-Cellular Therapeutics
lumateperone
schizophrenia
bipolar disorder
drug approvals
FDA
Flag link:
Amarin for $20B? Novartis' MedCo deal drives fresh buyout rumors for Vascepa's maker
Amarin for $20B? Novartis' MedCo deal drives fresh buyout rumors for Vascepa's maker
Fierce Pharma
Amarin
M&A
Novartis
Medicines Company
Gilead Sciences
Flag link:
Does Amarin Have a Dark Horse Suitor?
Does Amarin Have a Dark Horse Suitor?
Motley Fool
Amarin
Vascepa
M&A
Gilead Sciences
Flag link:
Looking for a Biotech Stock That's an Ideal Buyout Candidate? This Is It.
Looking for a Biotech Stock That's an Ideal Buyout Candidate? This Is It.
Motley Fool
Amarin
Vascepa
M&A
Amgen
Novartis
Pfizer
Flag link:
Acasti plays catch-up to Amarin’s Vascepa
Acasti plays catch-up to Amarin’s Vascepa
EP Vantage
Ascati
Amarin
Vascepa
CaPre
Flag link:
AHA: Amarin's Vascepa halts progression of arterial plaque in key study
AHA: Amarin's Vascepa halts progression of arterial plaque in key study
Fierce Pharma
Amarin
Vascepa
AHA
FDA
aterial plaque
Flag link:
What's next for Amarin? CEO John Thero talks Vascepa's label, pricing and future partnerships
What's next for Amarin? CEO John Thero talks Vascepa's label, pricing and future partnerships
Biopharma Dive
Amarin
Vascepa
John Thero
labeling
Flag link:
What's Next for Amarin's Stock?
What's Next for Amarin's Stock?
Motley Fool
Amarin
Vascepa
FDA
pharma stocks
advisory panels
Flag link:
FDA Advisory Committee Votes Unanimously in Favor of Expanding Amarin’s Vascepa Label
FDA Advisory Committee Votes Unanimously in Favor of Expanding Amarin’s Vascepa Label
RAPS.org
FDA
advisory panel
Amarin
Vascepa
Flag link:
Shares of Amarin rise on favorable opinion from FDA committee
Shares of Amarin rise on favorable opinion from FDA committee
Marketwatch
FDA
Amarin
Vascepa
Flag link:
Amarin (AMRN) Beats Earnings & Revenues Estimates in Q3
Amarin (AMRN) Beats Earnings & Revenues Estimates in Q3
Zacks.com
Amarin
earnings
Flag link:
The future of Vascepa sales, and Amarin, could hinge on next week's panel
The future of Vascepa sales, and Amarin, could hinge on next week's panel
EP Vantage
Amarin
Vascepa
FDA
advisory panels
M&A
Flag link:
J&J's Xarelto, Amarin's Vascepa are cost-effective, not budget friendly — ICER
J&J's Xarelto, Amarin's Vascepa are cost-effective, not budget friendly — ICER
Endpoints
ICER
drug pricing
JNJ
Xarelto
Amarin
Vascepa
Flag link:
Why Amarin Investors Have Their Eyes on Nov. 14
Why Amarin Investors Have Their Eyes on Nov. 14
Motley Fool
Amarin
Vascepa
FDA
Flag link:
ESC 2019 – Amarin hopes for guideline boost despite regulatory delay
ESC 2019 – Amarin hopes for guideline boost despite regulatory delay
EP Vantage
Amarin
Vascepa
ESC
European Society of Cardiology
Flag link:
Amarin's Vascepa buzzkill: FDA stalls label review with surprise panel meeting
Amarin's Vascepa buzzkill: FDA stalls label review with surprise panel meeting
Fierce Pharma
Amarin
Vascepa
advisory panels
FDA
Flag link:

Pages